Sukses Main Mahjong Ways Best808 Pahami Scatter dan Kombinasinya Mahjong Ways Best808 Simbol Scatter Meningkatkan Peluang Menang Kesalahan Umum Pemain Mahjong Ways di Best808 Auto Jackpot Strategi Terbaik Fitur Scatter Mahjong Ways Best808 Mahjong Ways Best808 Panduan Scatter Wild Hasil Maksimal Pola Mahjong Ways Best808 Gacor Scatter Menang Bongkar Misteri Mahjong Ways Best808 Kunci Kemenanganmu Mau Cuan Maksimal di Mahjong Ways Best808 Trik Menggunakan Scatter Agar Lebih Untung Main Mahjong Ways di Best808 Kenali Pola Scatter Free Spin Gandakan Kemenanganmu Rahasia Scatter Mahjong Ways Best808 Strategi Jitu Menang Jackpot Besar Misteri Scatter Mahjong Ways Tol777 Kunci Jackpot Besar Bongkar Rahasia Mahjong Ways Tol777 Fitur Scatter Pola Menang Mahjong Ways Tol777 Simbol Scatter Kemenangan Besar Main Mahjong Ways di Tol777 Cara Memanfaatkan Scatter Strategi Mahjong Ways Tol777 Rahasia Scatter Trik Menang Jackpot Analisis Pola Permainan Mahjong Ways Keunggulan Mahjong Ways Tol777 vs Tradisional Kombinasi Simbol Tertinggi Mahjong Ways Langkah Meningkatkan Keahlian Mahjong Ways Mahjong Ways Tol777 Berbeda dari Permainan Mengapa Mahjong Ways Tol777 Diminati Dunia Optimalkan Putaran Mahjong Ways Tol777 Sejarah Mahjong Ways Tol777 dan Keunikan Simbol Mahjong Ways Tol777 dan Pemanfaatannya Strategi Lanjutan Mahjong Ways Tol777 Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Cara Cepat Kuasai Mahjong Ways Tol777 Mengapa Mahjong Ways Tol777 Populer Mitos & Fakta Mahjong Ways Tol777 Strategi Pemula vs Pro Mahjong Ways Teknik Profesional Mahjong Ways Tol777 Mahjong Ways Tol777: Keberuntungan atau Skill? Mahjong Ways Tol777: Tradisi dan Inovasi Panduan Mahjong Ways Tol777 untuk Pemula Rahasia Menang Mahjong Ways Tol777 Tips Efektif Main Mahjong Ways Tol777 Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online main mahjong ways di malam hari jackpot profit mengamati permainan mahjong ways dengan baik dan benar merasa bosan pada malam hari? coba cara bermain mahjong ways ini minum kopi memotivasi bermain mahjong ways nelayan tebing tinggi pola mahjong ways hasil mencengangkan pelajar bandung download mahjong ways peluang besar trik dan pola mahjong ways pemuda belanda tato mahjong ways mengenang jackpot satu miliar pola rtp mahjong ways terbaik resep bermain mahjong ways dengan mudah slot mahjong ways dikenal sejak abad ke-11 hingga zaman milenial video mahjong ways viral menghebohkan warga indonesia warga jayamakmur dulu diremehkan, bermain mahjong ways hidup berlimpah harta unik keren bali cendera mata mahjong ways rp100000 warga bingung merek cat dinding sama mahjong ways RTP LIVE RTP LIVE RTP LIVE RTP LIVE RTP LIVE RTP LIVE RTP LIVE RTP LIVE RTP LIVE RTP LIVE RTP Live Mesin Gachor RTP Live Mesin Gachor RTP Live Mesin Gachor RTP Live Mesin Gachor RTP Live Mesin Gachor RTP Live Mesin Gachor RTP Live Mesin Gachor RTP Live Mesin Gachor RTP Live Mesin Gachor RTP Live Mesin Gachor Mesin RTP Live SEO Kacau Mesin RTP Live SEO Kacau Mesin RTP Live SEO Kacau Mesin RTP Live SEO Kacau Mesin RTP Live SEO Kacau Mesin RTP Live SEO Kacau Mesin RTP Live SEO Kacau Mesin RTP Live SEO Kacau Mesin RTP Live SEO Kacau Mesin RTP Live SEO Kacau Fitur Menarik Mahjong Ways BIL99 Menang Kejutan Mahjong Ways BIL99 Fitur Wajib Maksimalkan Putaran Mahjong Ways BIL99 Menang Menguasai Fitur Mahjong Ways BIL99 Menang Panduan Pemain Berpengalaman Mahjong Ways BIL99 Panduan Setiap Putaran Mahjong Ways BIL99 Strategi Unggulan Mahjong Ways BIL99 Tips Mengalahkan Lawan Mahjong Ways BIL99 Trik Ampuh Mahjong Ways BIL99 Putaran Trik Cerdas Peluang Menang Mahjong Ways BIL99

The Latest ObamaCare Assault On Health Care Innovation

The list of health services that ObamaCare requires all insurers to cover without co-pays or deductibles keeps growing. The latest additions include an array of “women’s wellness” services and products: birth control, breast pumps, domestic violence counseling, and more.

Of course, these additional benefits aren’t really “free.” They drive up the cost of health insurance.

ObamaCare’s proponents wave away concerns about rapidly spiraling health costs by citing the law’s mechanisms for extracting savings from the healthcare system, like its Patient-Centered Outcomes Research Institute. This federal body will undertake “comparative-effectiveness” research (CER), ostensibly to determine whether newer, more expensive treatments work as well as their older, cheaper counterparts.


CER’s cheerleaders claim that it will save the health care system billions by ensuring that we don’t waste money on pricey treatments that don’t work.

Those promises are overblown. Not only will CER fail to trim health spending — it will actually slow medical innovation.

President Obama simplistically explained CER by saying, “If there’s a blue pill and a red pill and the blue pill is half the price of the red pill and works just as well, why not pay half price for the thing that’s going to make you well?”

That line of thinking is attractive, particularly as our nation’s annual health tab is projected to increase by more than 75% by 2020, to $4.64 trillion — one-fifth of the U.S. economy. Who wouldn’t want to flush waste out of the system?

On its face, CER isn’t a bad thing. It’s a useful tool that can help doctors and patients make more informed health decisions.

But when applied from on high by government bureaucrats, CER can yield dangerous results.

A new study from my Pacific Research Institute colleague Dr. Ben Zycher indicates that the government-led CER process will depress investment in pharmaceutical and medical device research and development by 10% to 12% — about $10 billion per year.

Less investment in R&D means fewer revolutionary medical advances that can improve or extend our lives.

Previous published research suggests that historically, every $2,000 or so invested in pharmaceutical R&D produces an additional expected life-year in the United States. Drawing on this historical data, Zycher estimates that the CER-fueled loss of investment into medical research and development will deprive us of an expected five million life-years annually.

Those 5 million life-years represent, conservatively, some $500 billion in terms of the value of lost years.

Zycher pinpoints four reasons for the decline in investment — and thus in innovation. First, government-run CER will force producers to conduct CER trials of their own to evaluate whether it’s even worth submitting their drugs or technologies for government review. All those additional tests will increase R&D costs.

Second, the government has a strong incentive to “discover” that newer, more expensive treatments are not much better than older, cheaper ones. After all, the government pays for about half of all medical care. In an era of scarce resources, officials will face strong political pressures to avoid paying for expensive medical technologies — particularly if that money can be spent on programs that could benefit a wider swath of individuals. This raises the risk of nonapproval or limited approval, both for federal coverage programs, and generally.

Further, elected officials operate on different time horizons than do patients. Today’s research may not yield a cure for a decade or more — at great upfront expense. Future patients who may be the beneficiaries of that research don’t vote today — and so their interests may be sacrificed to deliver budget savings or other goodies to those who do currently vote.

Finally, CER will lengthen the amount of time required for a drug or medical technology to achieve regulatory approval. Each additional day a new treatment spends in limbo is a day it can’t try to recapture its R&D costs through patent-protected exclusive sales.

According to researchers at the Tufts Center for the Study of Drug Development, the average drug takes $1.3 billion and about a decade to develop. About 30% of that cost comes during the clinical trial phase, when CER would have the greatest impact.

Already, only three out of ten new medicines earn back their research and development costs. If CER further hamstrings the approval process for new medical technologies and minimizes the ability of firms to recoup their research and development costs, we’ll all be worse off in the long run — even if the government reaps some savings in the short term.

The Obama Administration has high hopes for CER as a cost-cutting tool. But by slowing medical innovation, comparative-effectiveness research will consign those hoping for new cures today to continued suffering — and deprive future generations of medical miracles we can only imagine.

Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

Scroll to Top